Literature DB >> 26491623

Progress in Making Ras as a Druggable Target.

Sibaprasad Bhattacharyya1.   

Abstract

Entities:  

Year:  2014        PMID： 26491623      PMCID： PMC4610733          DOI： 10.4172/2167-0501.1000e157

Source DB:  PubMed          Journal:  Biochem Pharmacol (Los Angel)        ISSN： 2167-0501


× No keyword cloud information.
  7 in total

Review 1.  Inhibition of Ras for cancer treatment: the search continues.

Authors:  Antonio T Baines; Dapeng Xu; Channing J Der
Journal:  Future Med Chem       Date:  2011-10       Impact factor: 3.808

2.  Inhibition of purified p21ras farnesyl:protein transferase by Cys-AAX tetrapeptides.

Authors:  Y Reiss; J L Goldstein; M C Seabra; P J Casey; M S Brown
Journal:  Cell       Date:  1990-07-13       Impact factor: 41.582

Review 3.  Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies?

Authors:  C W Reuter; M A Morgan; L Bergmann
Journal:  Blood       Date:  2000-09-01       Impact factor: 22.113

4.  Therapeutic strategies for targeting ras proteins.

Authors:  Stephan Gysin; Megan Salt; Amy Young; Frank McCormick
Journal:  Genes Cancer       Date:  2011-03

Review 5.  Ras oncogenes: split personalities.

Authors:  Antoine E Karnoub; Robert A Weinberg
Journal:  Nat Rev Mol Cell Biol       Date:  2008-07       Impact factor: 94.444

6.  Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling.

Authors:  Gunther Zimmermann; Björn Papke; Shehab Ismail; Nachiket Vartak; Anchal Chandra; Maike Hoffmann; Stephan A Hahn; Gemma Triola; Alfred Wittinghofer; Philippe I H Bastiaens; Herbert Waldmann
Journal:  Nature       Date:  2013-05-22       Impact factor: 49.962

7.  K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions.

Authors:  Jonathan M Ostrem; Ulf Peters; Martin L Sos; James A Wells; Kevan M Shokat
Journal:  Nature       Date:  2013-11-20       Impact factor: 49.962
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.